Related Experiment Video
Updated: Jun 10, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Fluoroquinolone-Induced Multisystem Toxicity: A Case Report
Zakary D Landers1, Asra Mazhar2
1Osteopathic Medicine, Pacific Northwest University of Health Sciences, Yakima, USA.
Abstract:
Fluoroquinolones are widely prescribed antibiotics with well-known, mostly transient adverse effects, the most common of which are gastrointestinal disturbances, headaches, dizziness, rash, etc. However, a less recognized yet profoundly debilitating complication exists known as fluoroquinolone-associated disability (FQAD), operationally defined as impacting at least two systems (neurological, musculoskeletal, psychiatric, and/or cardiovascular) for at least 30 days post-cessation of a fluoroquinolone and with an outcome reported as disability. Unfortunately, this syndrome has yet to be formally recognized by the medical community. As such, FQAD patients are rarely diagnosed and undergo extensive diagnostic testing, leading to unnecessary costs to the patient and our healthcare system. Herein, we present the case of a 41-year-old male patient who developed acute bilateral numbness and tingling in his upper and lower extremities after just two doses of ciprofloxacin for epididymitis. Despite extensive evaluations from various specialists and therapists over the following 18 months, his symptoms continued to progress without any clear insight into the cause of his symptoms. He eventually reached out to an FQAD specialist due to his own suspicions and began therapy with hyperbaric oxygen, IV magnesium, and IV glutathione. Mild improvement was noted from these therapies, but he was unable to undergo regular treatments due to the financial debt acquired from his extensive medical workups and ultimately stopped treatment completely without any further improvements. Our case report highlights the importance of early recognition of FQAD to start prompt treatment and avoid costly testing. Overall, we aim to raise awareness of FQAD among clinicians as a potential complication of fluoroquinolone use.
Insights
Fluoroquinolone-associated disability (FQAD) is a severe condition affecting multiple systems, often diagnosed late. Early recognition of FQAD is crucial for prompt treatment and avoiding extensive, costly medical evaluations.
Area of Science:
- Pharmacology
- Neurology
- Toxicology
Background:
- Fluoroquinolones are common antibiotics with known side effects.
- Fluoroquinolone-associated disability (FQAD) is a severe, underrecognized complication impacting multiple body systems for over 30 days post-antibiotic cessation.
Observation:
- A 41-year-old male developed acute bilateral extremity numbness and tingling after two ciprofloxacin doses.
- Despite 18 months of extensive specialist evaluations, the cause remained undiagnosed, leading to symptom progression.
Findings:
- The patient, suspecting FQAD, underwent therapies including hyperbaric oxygen and IV magnesium/glutathione, showing mild improvement.
- Treatment cessation due to financial burden from prior workups resulted in no further symptom improvement.
Implications:
- This case underscores the critical need for early FQAD recognition to initiate timely treatment and prevent unnecessary diagnostic costs.
- Raising clinician awareness of FQAD as a potential fluoroquinolone complication is essential for improved patient outcomes.
Related Concept Videos
Drug Toxicity: Overview
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions
Drug toxicity: Idiosyncratic Reactions
Pharmaceutical Poisoning: Potential Scenarios
Inhibitors of Bacterial DNA Synthesis

